Microbot Medical Inc. (NASDAQ: MBOT) today announced the
revealing of LIBERTYTM, the world’s first fully disposable robotic
system for use in neurovascular, cardiovascular and peripheral
vascular procedures. The LIBERTY robotic system features a unique
compact design with the capability to be operated remotely, reduce
radiation exposure and physical strain to the physician, as well as
the potential to eliminate the use of multiple consumables through
its “One & Done” capabilities. Microbot is set to publicly
display and demonstrate LIBERTY to investors, journalists and
healthcare industry leaders on Monday, January 13, 2020, in San
Francisco.
A Media Snippet accompanying this announcement
is available by clicking on the image or link below:
“LIBERTY is set to revolutionize the way
surgical robotics are being used in endovascular procedures, by
eliminating the need for capital equipment, reducing radiation
exposure and aiming to streamline the use of disposables during
these complex procedures,” commented Harel Gadot, Chief Executive
Officer, President, and Chairman. “In addition, with LIBERTY’s
remote operation as well as its “One & Done” capabilities, we
believe it has the potential to be the first system to democratize
endovascular interventional procedures.”
LIBERTY is set to revolutionize the way surgical
robotics are being used in endovascular procedures, by eliminating
the need for capital equipment, reducing radiation exposure and
aiming to streamline the use of disposables. -Harel Gadot, CEO
of Microbot.
Click to tweet link: https://ctt.ac/9DV2b
Dr. Eyal Morag, an ABR certified Interventional
Radiologist and Chairman of Radiology and Nuclear Medicine at
Assuta Ashdod Medical Center in Israel, will be performing the live
demonstrations highlighting the unique capabilities of
LIBERTY.
“I believe LIBERTY will be welcomed by the
interventional community due to its clinical and technical benefits
in various subspecialties, such as neurovascular, cardiovascular
and peripheral vascular interventions,” commented Dr. Morag. “The
system set up is easy and straightforward, and it offers intuitive
remote operation capabilities. These features are designed to
reduce radiation exposure and eliminate physical strain on the
physicians. Lastly, I believe it will democratize vascular
procedures by shortening the physician’s learning curve.”
Unveiling/Demonstration Event &
Webcast Video
To attend the LIBERTY unveiling and demonstration event on
Monday, January 13, at 7:00 am PT, please contact Michael Polyviou
at 732-933-2754 or mpolyviou@evcgroup.com.
Members of the media should contact Erich Sandoval at
212-867-1762 or erich.sandoval@finnpartners.com.
Monday, January 13, at 10:00 am ETThe full presentation of the
unveiling and demonstration will be available and may be accessed
in the ‘Investors’ section of the Company’s website at
www.microbotmedical.com.
Additionally, the Company will be hosting
One-on-One meetings in San Francisco on Monday, January 13,
beginning at 9:00 am PT, through Wednesday, January 15, at 3:00 pm
PT. To schedule a One-on-One meeting and a private demonstration,
please contact Michael Polyviou at 732-933-2754 or
mpolyviou@evcgroup.com.
About Microbot Medical,
Inc.
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, focused primarily on
both natural and artificial lumens within the human body.
Microbot’s current proprietary technological platforms provide the
foundation for the development of a Multi Generation Pipeline
Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel
Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of
improving clinical outcomes for patients and increasing
accessibility through the use of micro-robotic technologies.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development, and potential opportunities for Microbot Medical Inc.
and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products,
including LIBERTY, the outcome of its studies to evaluate the SCS
and other existing and future technologies, uncertainty in the
results of pre-clinical and clinical trials or regulatory pathways
and regulatory approvals, need and ability to obtain future
capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the businesses of Microbot
Medical Inc. particularly those mentioned in the cautionary
statements found in Microbot Medical Inc.’s filings with the
Securities and Exchange Commission. Microbot Medical disclaims any
intent or obligation to update these forward-looking
statements.
Investor Contact:
Michael PolyviouEVC
Groupmpolyviou@evcgroup.com 732-933-2754
Media Contact:
Erich SandovalFinn
Partnerserich.sandoval@finnpartners.com212-867-1762
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2023 to Apr 2024